Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly (Q36475343)

14 August 2017

1 reference

title

Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly (English)

1 reference

14 August 2017

0 references

1 reference

Terry A Jacobson

1

0 references

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

29

1 reference

14 August 2017

5

1 reference

14 August 2017

421-448

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200629050-00005

14 August 2017

0 references

cites work

Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP).

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629050-00005

Statin-associated myopathy with normal creatine kinase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629050-00005

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629050-00005

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629050-00005

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629050-00005

Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629050-00005

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629050-00005

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629050-00005

Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.

21 January 2018

1 reference

12 December 2020

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Low prevalence of lipid lowering drug use in older men with established coronary heart disease

1 reference

12 December 2020

The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events

1 reference

12 December 2020

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1 reference

12 December 2020

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

1 reference

12 December 2020

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

1 reference

12 December 2020

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

1 reference

12 December 2020

Safety of statins: focus on clinical pharmacokinetics and drug interactions

1 reference

12 December 2020

Rhabdomyolysis and statin therapy: relevance to the elderly

1 reference

12 December 2020

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

1 reference

12 December 2020

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy

1 reference

12 December 2020

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

12 December 2020

Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia

1 reference

12 December 2020

Increasing prevalence of the metabolic syndrome among u.s. Adults.

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Preventing clinically evident coronary heart disease in the postmenopausal woman

1 reference

12 December 2020

Age as a risk factor: you are as old as your arteries

1 reference

12 December 2020

Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitat

1 reference

12 December 2020

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

1 reference

12 December 2020

Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study

1 reference

12 December 2020

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

12 December 2020

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis

1 reference

12 December 2020

Safety of rosuvastatin

1 reference

12 December 2020

The liver and lovastatin

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis

1 reference

12 December 2020

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

1 reference

12 December 2020

Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis

1 reference

12 December 2020

Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).

1 reference

12 December 2020

Total cholesterol and risk of mortality in the oldest old.

1 reference

12 December 2020

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

1 reference

12 December 2020

Hepatotoxicity of hypolipidemic drugs

1 reference

12 December 2020

Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

1 reference

12 December 2020

Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly

1 reference

12 December 2020

Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program

1 reference

12 December 2020

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

1 reference

12 December 2020

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

1 reference

12 December 2020

The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk

1 reference

12 December 2020

Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data

1 reference

12 December 2020

Electron beam computed tomography and coronary artery disease: scanning for coronary artery calcification

1 reference

12 December 2020

Tracking women's awareness of heart disease: an American Heart Association national study

1 reference

12 December 2020

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

12 December 2020

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia

1 reference

12 December 2020

Pravastatin Therapy and the Risk of Stroke

1 reference

12 December 2020

Managing dyslipidemia in chronic kidney disease

1 reference

12 December 2020

Measuring the effect of risk factors on coronary atherosclerosis: coronary calcium score versus angiographic disease severity.

1 reference

12 December 2020

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

12 December 2020

Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors

1 reference

12 December 2020

Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?

1 reference

12 December 2020

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

1 reference

12 December 2020

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

1 reference

12 December 2020

Statins and hepatotoxicity: focus on patients with fatty liver

1 reference

12 December 2020

Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).

1 reference

12 December 2020

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

12 December 2020

The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol

1 reference

12 December 2020

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

12 December 2020

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

12 December 2020

Rosuvastatin-induced arrest in progression of renal disease

1 reference

12 December 2020

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1 reference

12 December 2020

Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

1 reference

12 December 2020

Evidence-based guidelines for cardiovascular disease prevention in women 11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, p

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study

1 reference

12 December 2020

FDA adverse event reports on statin-associated rhabdomyolysis

1 reference

12 December 2020

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

1 reference

12 December 2020

Relation of coronary calcium score by electron beam computed tomography to arteriographic findings in asymptomatic and symptomatic adults

1 reference

12 December 2020

Autoimmune hepatitis revealed by atorvastatin

1 reference

12 December 2020

Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox

1 reference

12 December 2020

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

12 December 2020

The Lescol ® Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease

1 reference

12 December 2020

Cholesterol lowering in the older population: time for reassessment?

1 reference

12 December 2020

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

12 December 2020

Do statins cause cancer? A meta-analysis of large randomized clinical trials

1 reference

12 December 2020

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

1 reference

12 December 2020

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

12 December 2020

The issue of statin safety: where do we stand?

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

12 December 2020

Is a high serum cholesterol level associated with longer survival in elderly hypertensives?

1 reference

12 December 2020

The challenge of health care delivery to the elderly patient with cardiovascular disease. Demographic, epidemiologic, fiscal, and health policy implications

1 reference

12 December 2020

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

1 reference

12 December 2020

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

12 December 2020

Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group

1 reference

12 December 2020

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

1 reference

12 December 2020

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Current overview of statin-induced myopathy

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

1 reference

12 December 2020

Liver transplantation for acute liver failure from drug induced liver injury in the United States

1 reference

12 December 2020

Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?

1 reference

12 December 2020

Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack

1 reference

12 December 2020

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

12 December 2020

Frequency of creatine kinase elevation during treatment with fluvastatin

1 reference

12 December 2020

No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Statin-associated myopathy

1 reference

12 December 2020

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

1 reference

12 December 2020

Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group

1 reference

12 December 2020

Combination therapy for dyslipidemia: safety and regulatory considerations

1 reference

12 December 2020

Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety

1 reference

12 December 2020

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

1 reference

12 December 2020

New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population

1 reference

12 December 2020

Defining patient risks from expanded preventive therapies

1 reference

12 December 2020

Rapid increase in statins newly dispensed to Ontario seniors between 1994 and 2000.

1 reference

12 December 2020

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

12 December 2020

10.2165/00002018-200629050-00005

Identifiers

DOI

1 reference

PubMed ID

16689557

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16689557